Markets· August 16, 2026 at 06:02 p.m.
Quanterix Restructures Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Key takeaways
- Quanterix restructures sales team
- Targets $10 million diagnostics revenue by 2026
- FDA decision for Alzheimer's blood test expected Q4/Q1
Quanterix Corporation, a life sciences and diagnostics company, is reorganizing its sales team to focus on specific areas: spatial biology, Simoa products, and clinical-trial services. The move comes after the company found its previous combined-sales model too burdensome. Jim Gute has been appointed as the new chief commercial officer. Quanterix aims to achieve $10 million in diagnostics revenue by 2026 and is targeting an FDA decision for its Alzheimer's blood test in Q4, potentially extending into Q1.
